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Objectives: Ischaemic complications occur in 15–20% of
patients with giant cell arteritis (GCA). The aim of our
study was to explore the effect of mesenchymal growth
factors expressed in GCA lesions on myointimal cell
responses related to the development of intimal
hyperplasia and vessel occlusion.
Methods: We developed a method to obtain primary
human temporal artery derived myointimal cells
(HTAMCs) based on the culture of temporal artery
sections on Matrigel.
Results: Among the factors tested (platelet-derived
growth factor (PDGF)-AB, fibroblast growth factor (FGF)-2,
vascular endothelial growth factor (VEGF), epidermal
growth factor (EGF), transforming growth factor (TGF)b,
chemokine (C-C motif) ligand (CCL)2, interleukin (IL)6 and
IL1b), PDGF exhibited the strongest activity in inducing
HTAMC proliferation and migration. As assessed by
protein array, immunoassay and quantitative real-time
reverse transcriptase (RT)-PCR, PDGF stimulated matrix
proteins (collagen I, collagen III and fibronectin) as well as
CCL2 and angiogenin production by HTAMCs. Imatinib
mesylate inhibited PDGF-mediated activation of signalling
pathways (Src, extracellular signal-regulated kinase (ERK)
and Akt phosphorylation) related to cell motility and
survival, efficiently resulting in inhibition of PDGF-induced
HTAMC responses. Myointimal cell outgrowth from
cultured temporal artery sections from patients with GCA,
where multiple interactions take place, was also
efficiently reduced by imatinib.
Conclusion: Among several mediators produced in
GCA, PDGF has the highest vaso-occlusive potential.
PDGF may also contribute to disease perpetuation by
stimulating the production of angiogenic factors
(angiogenin) and chemoattractants (CCL2). Imatinib
mesylate strongly inhibits PDGF-mediated responses,
suggesting a therapeutic potential to limit vascular
occlusion and ischaemic complications in large vessel
vasculitis.
Giant cell arteritis (GCA) is a chronic inflamma-
tory disease involving large-sized and medium-
sized vessels.1–3 Vascular remodelling in response
to inflammation leads to intimal hyperplasia
resulting in lumen occlusion and ischaemia of
supplied tissues.4–7 In GCA, the most frequent
and devastating ischaemic events occur in terri-
tories supplied by carotid and vertebral artery
branches, and include ischaemic optic neuritis
and stroke.8 About 10–15% of patients also
develop an occlusive vasculopathy involving
large-sized and medium-sized vessels, particularly
the aortic arch and limbs.9 These vascular
occlusive complications may occur during the
follow-up of patients who underwent a satisfac-
tory response of classical disease-related symp-
toms to corticosteroid therapy.9 Moreover, when
large vessel stenoses occur, response to steroids is
less complete and more unpredictable and
patients may require angioplasty or derivative
surgery.9 Vascular occlusion is even more frequent
in Takayasu disease, another large vessel granu-
lomatous vasculitis.10 Although GCA and
Takayasu disease differ in their demographic
and ethnic distribution, their histopathological
features are nearly identical and both diseases
may share immunopathogenic mechanisms.2 11
Under the influence of a variety of signals,
vascular smooth muscle cells (VSMC) react to
injury by evolving from their quiescent, contrac-
tile phenotype to proliferating, migratory and
extracellular matrix (ECM)-secreting myointimal
cells, key players in the development of intimal
hyperplasia and vessel occlusion.4 7 12 13 Expression
of several factors able to stimulate proliferation of
mesenchymal cells has been demonstrated in GCA
lesions. These include platelet-derived growth
factor (PDGF), transforming growth factor b
(TGFb), interleukin 1b (IL1b), IL6, fibroblast
growth factor 2 (FGF-2) and vascular endothelial
growth factor (VEGF), among others.2 3 5 14–16
Some of these factors have also been detected in
Takayasu disease.2 11 Most of our current under-
standing of the pathogenic mechanisms leading to
GCA comes from studies performed in temporal
artery biopsies.2 3 5–7 14–16 To gain a better under-
standing of the mechanisms leading to vascular
occlusion in GCA, we developed a system to
obtain and culture myointimal cells from tem-
poral arteries (HTAMCs) in order to assess the
effects of various mediators on biological
responses related to the development of intimal
hyperplasia such as proliferation, migration and
ECM production.
Among the factors tested, PDGF exhibited the
strongest activity in our system. Given that
imatinib mesylate, an inhibitor of the tyrosine
kinase activity of the oncogenic protein BCR/ABL
generated in chronic myeloid leukaemia, may also
inhibit PDGF receptor-mediated signalling,18–20 we
tested the effect of this compound on PDGF-
induced responses in our model. We found that
imatinib inhibited HTAMC biological responses
related to the development of intimal hyperplasia.
Our findings suggest that imatinib might be a
therapeutic option to limit occlusive vasculopathy
in large vessel vasculitis.
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MATERIALS AND METHODS
Reagents
Recombinant human TGFb, IL1b, IL6, epidermal growth factor
(EGF), monocyte chemoattractant protein-1 (CCL2/MCP-1),
FGF-2, VEGF, purified PDGF-AB and neutralising mAb against
PDGF receptor a (clone 35248) were obtained from R&D
Systems (Minneapolis, Minnesota, USA). Imatinib mesylate
(Gleevec) was kindly provided by Novartis Pharmaceuticals
(Basel, Switzerland).
Isolation and culture of myointimal cells from human temporal
arteries
Serial, 1 mm thick sections from temporal artery fragments,
obtained for diagnostic purposes, were placed onto ice-cold
reconstituted basement membrane Matrigel (BD Biosciences,
San Jose, California, USA) and cultured in Dulbecco modified
Eagle medium (DMEM)/10% foetal bovine serum (FBS) at 37uC
in 5% CO2. HTAMCs developed from the explanted sections
within 1 week (fig 1A) and reached confluence in 3 weeks. Cells
were then released with trypsin/EDTA (Invitrogen), transferred
to uncoated flasks, and split 1:2 upon confluence. The
myointimal cell phenotype21 was verified by confirming expres-
sion of smooth muscle actin by flow cytometry and type I and
III collagens by real-time reverse transcriptase (RT)-PCR as
described below. In all the experimental conditions tested, cell
viability was confirmed by trypan blue exclusion.
The study was approved by the institutional review board of
the Hospital Clı´nic of Barcelona and all patients signed an
informed consent.
Flow cytometry analysis of a smooth muscle actin expression
Cells were harvested with trypsin/EDTA, gently fixed with 4%
paraformaldehyde for 1 h at 4uC, permeabilised with 0.2%
Tween 20 in phosphate buffered saline (PBS), and incubated
with a mAb anti-a smooth muscle actin (clone 1A4, Dako,
Glostrup, Denmark) for 30 min at 4uC, and, subsequently, with
a goat anti-mouse antibody (AlexaFluor488, Molecular Probes,
Eugene, Oregon, USA) for 30 min at 4uC. Both antibodies were
used at 1/100 dilution. Cells were analysed with a fluorescence-
activated cell sorter (FACScan, Becton Dickinson, San Jose,
California, USA).
Proliferation assay
Proliferation was assessed as previously described.6 16 Briefly,
HTAMCs were plated in 96-well plates at 4000 cells/well in
DMEM and incubated at 37uC in 5%CO2 for 1 to 6 days, with
or without addition of the above listed growth factors. These
were used at concentrations ranging from 5–50 ng/ml, selected
on the basis of previously published data and preliminary
experiments. At several time-points, cells were fixed and stained
with 0.2% crystal violet (Sigma-Aldrich, Madrid, Spain) in 20%
methanol for 10 min. Wells were washed, air-dried, and
solubilised in 1% sodium dodecyl sulfate (SDS). Optical density
was measured at the 600 nm wavelength.
In some experiments, HTAMC proliferation was also assessed
using the 3-(4,5-dimethylthiazol-2-yl)-5-diphenyltetrazolium
bromide (MTT) assay (Promega, Madison, Wisconsin, USA),
according to the instructions of the manufacturer.
Migration assay
HTAMC migration was measured in 48-well microchemotaxis
Boyden chambers with 0.1% gelatin-coated, 10 mm pore
polyester filters (Poretics, Osmonics Inc., Minnetonka,
Minnesota, USA). HTAMCs were placed at 5000/well in the
upper chambers. Growth factors were loaded at various
concentrations in the bottom chamber of quadruplicate wells.
After 6 h-incubation in 5% CO2 at 37uC, cells were removed
from the upper surface and filters were fixed with methanol and
Figure 1 Isolation, culture and
identification of human temporal artery
myointimal cells (HTAMCs). A. Primary
HTAMC outgrowth from temporal artery
rings cultured on Matrigel for 10 days
(1006magnification). B. Typical
appearance of confluent HTAMCs grown
on uncoated flasks (2006). C. Expression
of a smooth muscle actin by flow
cytometry. D. Kinetics of HTAMC growth
in Dulbecco modified Eagle medium
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stained with haematoxylin. Cells in five randomly selected
fields/well were counted under a microscope at 1256magnifi-
cation.
Western blot analysis
Assessment of protein phosphorylation by Western blot was
performed as described.22 Briefly, cell lysates were obtained in
modified radioimmunoprecipitation assay (RIPA) buffer and
supplemented with protease inhibitors (Complete, Boehringer
Mannheim, Mannheim, Germany) and Na3VO4 at 200 mM. A
total of 20 mg of protein per lane was subjected to SDS-
polyacrilamide gel electrophoresis (PAGE) (8%) and blotted onto
nitrocellulose membranes (Invitrogen, Carlsbad, California,
USA). Blocked membranes were incubated overnight at 4uC
with rabbit anti-human Src, Akt, or ERK phosphorylated at
different residues. Immunodetection was performed with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit anti-
body at 1:2000 dilution. Blots were stripped and re-probed with
rabbit anti-human Src, Akt and ERK antibodies. All primary
antibodies were from Cell Signaling Technology (Beverly,
Massachusetts, USA) and were all used at 1:1000 dilution.
Assessment of protein secretion by protein array and
immunoassay
A Quantimatrix ELISA kit (Chemicon, Temecula, California,
USA) was used to measure fibronectin in HTAMC supernates
and cell lysates. A custom RayBio Human Cytokine Antibody
Array (RayBiotech, Inc. Norcross, Georgia, USA) was designed
to compare release of 30 inflammatory mediators of interest in
the supernates of PDGF-stimulated vs control HTAMCs. CCL2
and angiogenin concentrations in HTAMC supernates were
quantified with specific ELISA kits (Quantikine, R&D Systems,
Minneapolis, Minnesota, USA) according to the manufacturer’s
instructions.
Quantative real-time reverse transcription (RT)-PCR
Total RNA was extracted from cultured HTAMCs using TRIzol
Reagent (Invitrogen). Total RNA (1 mg) was reverse transcribed
using Archive kit (Applied Biosystems, Foster City, California,
USA). Collagen I (COL1A1) and III (COL3A1) mRNA were
measured by quantitative real-time RT-PCR with specific
predeveloped TaqMan gene expression assays from Applied
Biosystems. Detailed methodological aspects have been given in
previous publications.3 5 6 16 Fluorescence was detected with an
ABI PRISM 7900 Sequence Detection system and results were
analysed with the Sequence Detection Software V 1.6.3
(Applied Biosystems). All samples were normalised to the
expression of the endogenous control GUSb. Comparative CT
method was used to assess the relative gene expression of
COL1A1 and COL3A1.
HTAMC outgrowth from ex vivo cultured temporal artery
sections from patients with GCA
Temporal artery sections obtained from five untreated patients
with biopsy-proven GCA and eight controls were cultured on
Matrigel in the presence or in the absence of imatinib mesylate.
We also tested in this system a similar size fragment of an aortic
aneurysm surgically excised from a patient with GCA treated
with corticosteroids for 4 years. This specimen showed mild
remaining inflammatory infiltrates in the media. Daily photo-
graphs were taken from day 3 to day 17. Outgrowth of
HTAMCs was scored by two investigators blinded to the
conditions tested, as follows: 1 = visible outgrowth of scattered
cells; 2 = cells growing from the entire ring; 3 = cells expanding
at least two times the length of 2; and 4 = cells covering the
entire surface of the well. Agreement was achieved in 96% of
measurements. When there was discrepancy in the first
assessment, consensus was reached after re-evaluation.
Statistical analysis
Quantitative data were compared with the Mann–Whitney U
test. The Kruskal–Wallis test was used for multiple compar-
isons.
RESULTS
Culture and characterisation of HTAMCs
After the first passage, HTAMCs were able to grow on uncoated
tissue culture flasks with no addition of growth factors other
than FBS (fig 1B). Flow cytometry analysis revealed a
homogeneous cell population with .90% of cells expressing a
smooth muscle actin (fig 1C). HTAMCs doubled in 5–6 days
(fig 1D) and were used for experiments between passages 3 and
6. Cells survived for at least 10 doublings with no apparent
changes in cell morphology, phenotype, or growth rate. No
apparent differences in morphology or growth rate could be
observed between cells obtained from positive biopsies and
those obtained from normal temporal arteries, indicating that
proliferative and migratory activities relevant to the generation
of intimal hyperplasia that occur in inflamed arteries are not
intrinsic and mainly depend on stimuli present in the
microenvironment.
Comparative effects of mesenchymal cell growth factors on in
vitro HTAMC proliferation and migration
We next tested the effect of PDGF-AB, IL1b, IL6, CCL2, FGF-2,
TGFb, VEGF and EGF on HTAMC proliferation and migration.
These factors were considered relevant candidates to provide the
microenvironmental stimuli necessary for myointimal cell
activation because of their known ability to stimulate mesench-
ymal cell proliferation and their previously demonstrated
expression in GCA lesions.5 14–16 Among the factors tested,
PDGF elicited the highest stimulation of HTAMC proliferation
in a dose-dependent manner (fig 2A,B). FGF-2, IL1b, TGFb, and
EGF also induced HTAMC proliferation but to a lesser extent
(fig 2A,C). PDGF-induced HTAMC proliferation was abrogated
by a blocking mAb against the PDGF-receptor a (fig 2B),
confirming the specificity of the response.
Given that the development of intimal hyperplasia requires
not only myointimal cell proliferation but also migration
towards the lumen, we explored the effects of the above
growth factors on HTAMC migration in Boyden chambers. As
shown in table 1, PDGF had the strongest activity in inducing
HTAMC migration. Maximum activity was obtained at
concentrations of 10–20 ng/ml. EGF also increased cell migra-
tion but to a lesser extent. At the range of concentrations tested,
the remaining factors did not stimulate HTAMC motility
(table 1).
Inhibition of PDGF-induced HTAMC growth and migration by
imatinib mesylate
As shown in fig 2B, the effect of PDGF on cell proliferation was
inhibited with a function-blocking monoclonal antibody against
PDGF receptor a. Since imatinib inhibits tyrosine kinase activity
of the PDGF receptor, we tested its ability to inhibit PDGF-
induced activation of signalling pathways related to cell
survival, proliferation and migration in HTAMCs, given the
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relevance of these responses in the development of intimal
hyperplasia. As shown in fig 2D, treatment with PDGF resulted
in an efficient activation of Akt, a pivotal enzyme transducing
antiapoptotic signals,23 and Akt phosphorylation was strongly
inhibited by imatinib. PDGF also increased ERK1/2 and p60 Src
activation, crucial pathways in cell proliferation and migra-
tion24 25, which decreased upon imatinib treatment.
We next assessed whether the inhibitory effects of imatinib
on PDGF–activated signalling pathways resulted in an efficient
reduction of HTAMC responses. As displayed in fig 3A–C,
imatinib efficiently inhibited PDGF-induced cell growth and
motility. No inhibitory effect of imatinib was observed on
spontaneous, FGF-2, or EGF-induced HTAMC proliferation or
migration (fig 3B, and data not shown).
Imatinib mesylate inhibits PDGF-induced extracellular matrix
production by HTAMCs
Since neointima formation requires not only myointimal
cell proliferation and migration but also excessive matrix
deposition, we next investigated the impact of imatinib on
PDGF-induced ECM production by HTAMCs. Among poten-
tially relevant matrix proteins, we investigated fibronectin,
given its key function in supporting integrin-dependent cell
proliferation and migration. We also focused on collagen I and
collagen III, the major structural collagens of blood vessels. As
shown in fig 3D–F, PDGF significantly upregulated soluble and
cell-associated fibronectin, as well as collagen I and collagen III
production by HTAMCs. These effects were efficiently reduced
by imatinib.
Imatinib mesylate inhibits PDGF-induced HTAMC responses
related to persistence of inflammatory activity
We investigated additional PDGF-mediated responses poten-
tially contributing to amplify vascular inflammation in GCA.
We designed an antibody-based protein array with 30 inflam-
matory mediators to screen for PDGF-induced molecules in
HTAMCs. Mediators screened were selected according to their
previously demonstrated expression in GCA or their role in the
Figure 2 Effect of mesenchymal growth
factors on human temporal artery derived
myointimal cell (HTAMC) proliferation. A.
Proliferation of serum-starved HTAMCs
incubated for 6 days with the displayed
growth factors at 10 ng/ml. B. Inhibition
of HTAMCs by a function-blocking mAb
against the platelet-derived growth factor
(PDGF)-receptor a, added at 10 mg/ml, 60
min before exposure to PDGF (10 ng/ml).
C. Dose response of several growth
factors on serum-starved HTAMC
proliferation at day 6. Proliferation was
assessed by crystal violet staining.
Experiments were repeated three times
and one representative experiment is
shown. In all figures, symbols/bars
represent mean (standard error of the
mean (SEM)). *p,0.05, **p,0.01 and
***p,0.001 by Kruskal–Wallis test. D.
Effect of imatinib on PDGF-induced
activation of Akt, extracellular signal-
regulated kinase (ERK) and Src in
HTAMCs. Western blot detection of Akt,
ERK and p60Src, phosphorylated at the
indicated residues, in control or PDGF-
stimulated HTAMCs, in the presence or
absence of imatinib. Subconfluent
HTAMCs were serum-starved for 24 h,
preincubated with imatinib (1 mM) for 60
min and treated with PDGF-AB (10 ng/ml)
for 20 min. Blots are representative of
three independent experiments.
Table 1 Migration of human temporal artery derived myointimal cells (HTAMCs) (cell number/field) in
response to increasing concentrations of growth factors (ng/ml)
0 2.5 5 10 20
PDGF 44 (5.3) 68.7 (6.3)* 87.63 (4.6)** 101.4 (5.0)** 122.4 (3.9)**
EGF 44 (5.3) 66.8 (1.7)* 77.8 (6.2)* 79.3 (3.4)** 71 (4.6)*
VEGF 48.6 (3.5) 41.6 (1.6) 48 (3.5) 50.7 (2.1) 47.4 (2.1)
CCL2 48.6 (3.5) 47.3 (4.2) 37.1 (2.3) 47.3 (3.2) 49.6 (3.3)
IL1b 52.4 (2.9) 58.5 (4.0) 59.4 (4.0) 54.2 (4.1) 48.5 (4.1)
FGF-2 53.7 (2.4) 57.1 (5.1) 64.6 (2.6) 65.1 (3.0) 58.8 (3.6)
All values mean (standard error of the mean (SEM)). *p,0.05; **p,0.01 by Kruskal–Wallis test.
CCL, chemokine (C-C motif) ligand; EGF, epidermal growth factor; FGF, fibroblast growth factor; IL, interleukin; PDGF, platelet-
derived growth factor; VEGF, vascular endothelial growth factor.
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regulation of inflammatory, angiogenic, or fibrogenic responses,
given that these are considered relevant in disease perpetuation
or vascular occlusion (fig 4A,B). Among the surveyed factors,
PDGF significantly upregulated CCL2 and angiogenin produc-
tion by HTAMCs in a dose-dependent manner and this
increased expression was abrogated by imatinib (fig 4C,D).
Imatinib mesylate strongly reduces HTAMC outgrowth from ex
vivo cultured temporal artery explants
PDGF may not be the only factor contributing to intimal
hyperplasia in GCA. In order to assess whether the inhibitory
effects of imatinib on PDGF-induced HTAMC responses could
be overcome by other factors present in GCA lesions, we
explored the effect of imatinib on HTAMC outgrowth from
cultured temporal artery sections from five patients with GCA
and eight controls. As shown in fig 5, imatinib efficiently
reduced, but not abrogated, HTAMC outgrowth from cultured
artery sections, a complex system including multiple cell
interactions and mediators. No significant differences were
found between normal and GCA specimens, indicating that
PDGF is a significant factor in inducing myointimal cell
differentiation and growth in response to inflammatory and
physical (sectioning) injury.
DISCUSSION
We successfully developed a new method to expand myointimal
cells derived from thin arterial sections, using reconstituted
basement membrane Matrigel as an anchorage-providing
system. Our method has the advantage of requiring just a thin
arterial section, which is very important since the major portion
of the specimens excised must be processed to rule out or
confirm the histopathological diagnosis of GCA. This system
may be also applied to efficiently grow myointimal cells
obtained from other vascular beds, when there is paucity of
tissue or the vessels are small. Most of the studies investigating
smooth muscle cell biology have been performed with cells of
Figure 3 Effect of imatinib on platelet-
derived growth factor (PDGF)-induced
human temporal artery derived
myointimal cell (HTAMC) proliferation,
migration and extracellular matrix
production. A. Cell proliferation in
response to PDGF in the absence and in
the presence of imatinib (3-(4,5-
dimethylthiazol-2-yl)-5-
diphenyltetrazolium bromide (MTT)
assay). Cells were serum-deprived for 24
h, preincubated with imatinib (1 mM) for
60 min, and exposed to PDGF-AB (10 ng/
ml) for 5 days. B. Cell proliferation in
response to fibroblast growth factor
(FGF)-2 (10 ng/ml) in the absence and in
the presence of imatinib. C. Cell migration
as described in the Materials and
methods section. D. Fibronectin
concentration in the supernates of serum-
free, PDGF-stimulated HTAMCs in the
presence or in the absence of imatinib. To
detect cell-associated fibronectin in
addition to that released to the medium,
fibronectin content was also measured in
cell lysates. Cell lysates and supernates
were collected after 3 days of exposure
to PDGF with or without imatinib.
Fibronectin concentration was normalised
to cell content, assessed by crystal violet
staining. Detection was performed in
duplicate wells. The experiment was
performed three times with equivalent
results. Panels (E) and (F) show collagen I
and collagen III mRNA concentrations in
HTAMCs, respectively, cultured as in (A)
and collected after 24 h.
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aortic origin or aortic explants.26 27 Obtaining cells from targeted
vessels is important because VSMCs derived from different
vascular territories may have different phenotypes and func-
tional responses.28
In this study, we took advantage of this model to explore the
effects of several growth factors known to be expressed in GCA
lesions on HTAMC responses related to the development of
intimal hyperplasia.2 3 5 6 14–16 Among the factors tested, PDGF
exhibited the highest activity in stimulating HTAMC prolifera-
tion and migration. PDGF has been demonstrated to have
mitogenic and chemotactic activity on cultured aortic VSMC,
aortic explants and in in vivo models of arterial injury in other
territories.26 27 29–31 Based on these findings PDGF was proposed
as a candidate factor involved in the development of intimal
hyperplasia in GCA.4 Its expression by activated macrophages
was subsequently demonstrated in GCA lesions and was shown
to be associated with the development of cranial ischaemic
complications and clinically symptomatic large vessel stenoses.14
Our findings functionally demonstrate that PDGF is a major
growth factor for smooth muscle cells derived from arteries
involved by GCA lesions.
Imatinib mesylate was specifically designed as an ATP-
competitive inhibitor of the constitutive tyrosine kinase activity
of the fusion protein BCR/ABL generated in chronic myeloid
leukaemia.18–20 Imatinib was subsequently found to also inhibit
the tyrosine kinase activity of c-kit, the receptor for stem cell
factor (SCF) and PDGF receptor.19 20 Imatinib is an effective
therapy for patients with chronic myeloid leukaemia and
patients with gastrointestinal stromal tumours bearing onco-
genic mutations in the c-kit or PDGF receptors.19 20 Given that
imatinib has been used in a large number of patients with these
conditions with an excellent safety profile,19 32 33 we investigated
whether imatinib could inhibit PDGF-mediated responses
related to the development of intimal hyperplasia in
HTAMCs. Imatinib did not show any effect on resting cells,
but strongly inhibited PDGF-induced Akt, Src and ERK1/2
Figure 4 Effects of platelet-derived growth factor (PDGF) on chemokine (C-C motif) ligand (CCL)2 and angiogenin production by HTAMCs and
inhibition by imatinib. A. Design of the array membrane where 30 mediators are detected in duplicate spots. B. Mediators were detected by protein
array in serum-free supernates of human temporal artery derived myointimal cells (HTAMCs) with or without exposure to PDGF for 3 days. An increase
in CCL2 and angiogenin production can be observed. Exogenously added PDGF is also detected. C,D. CCL2 and angiogenin detection in the supernates
of HTAMCs incubated for 1 and 3 days, respectively, with increasing concentrations of PDGF in the presence or in the absence of imatinib (1 mM).
Results were normalised to cell number.
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phosphorylation, resulting in an efficient abrogation of PDGF-
induced HTAMC proliferation and migration. PDGF also induced
production of fibronectin and collagens I and III, the major
structural collagens of blood vessels. Through integrin-mediated
signals, fibronectin is able to support proliferation and migration
of inflammatory cells and VSMC.13 22 Treatment with imatinib
significantly reduced PDGF-induced fibronectin, collagen I and
collagen III production, suggesting that imatinib might be useful
in reducing intimal hyperplasia in GCA.
In addition to promoting fibrogenic responses, PDGF has
proinflammatory effects by stimulating certain nuclear factor
(NF)kB-mediated responses including chemokine production by
VSMC.26–34 PDGF also has an angiogenic activity in various
models and induces angiogenic factors such as VEGF and FGF-
2.17 35 36 Together, PDGF and PDGF-induced angiogenic mole-
cules may contribute to inflammation-induced angiogenesis, an
important mechanism supporting disease persistence in chronic
inflammatory diseases.
A survey of PDGF-induced molecules in HTAMCs revealed
significant upregulation of CCL2 and angiogenin. CCL2 is also an
angiogenic molecule and a potent chemoattractant for monocytes
and T helper (Th)1 lymphocytes, the main components of
inflammatory infiltrates in large vessel vasculitis.5 37 We have
recently shown that increased CCL2 expression is associated with
persistence of disease-activity in GCA.5 Although not fully
characterised for biological functions, angiogenin has angiogenic
activity in several systems.38 We found that imatinib efficiently
inhibited PDGF-induced CCL2 and angiogenin production by
HTAMCs. Together, these findings suggest that, besides reducing
intimal hyperplasia, imatinib may inhibit PDGF-driven proin-
flammatory activities potentially contributing to disease persis-
tence in large vessel vasculitis.
PDGF may not be the only factor promoting myointimal cell
proliferation and migration in GCA. To assess whether blocking
PDGF effects could be compensated in vivo by other factors, the
inhibitory effect of imatinib was tested in a temporal artery
culture system. Imatinib substantially reduced, but did not
abrogate, HTAMC outgrowth from cultured temporal artery
explants from patients with biopsy-proven GCA. A similar
effect was observed in an aortic specimen. Thus, imatinib had a
strong effect in a complex system containing all the cell
components and mediators participating in the development of
GCA lesions. The fact that imatinib does not interfere with
other factors and, accordingly, did not completely suppress
HTAMC outgrowth from GCA specimens is important given
that a certain extent of neointima formation may be necessary
to reinforce the vessel wall, preventing dilatation and rupture.
Imatinib also reduced myointimal cell outgrowth from normal
temporal arteries. Taken together, these findings indicate that
PDGF has a major, but not exclusive, role in driving vascular
response to inflammatory and physical injury.
In summary, imatinib inhibits cell responses related to the
development of intimal hyperplasia in HTAMCs and in a
temporal artery organ culture, suggesting a potential therapeutic
benefit in preventing the progression of vascular occlusion in
stenosing large vessel vasculitis. However, in the absence of in
vivo data, any therapeutic implication must be considered with
caution. Testing the effects of imatinib in animal models of large
vessel inflammation39 40 would add valuable information about
the potential of imatinib to reduce intimal hyperplasia in vivo.
Since there are no true animal models for GCA or Takayasu
disease, the efficacy and safety of imatinib in reducing vascular
occlusion in these diseases can only be assessed in clinical trials.
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Figure 5 Imatinib inhibits human temporal artery derived myointimal
cell (HTAMC) outgrowth from cultured temporal artery sections from
patients with giant cell arteritis (GCA). A. Temporal artery sections
exposed at the indicated concentrations of imatinib and cultured on
Matrigel for 15 days. HTAMC outgrowth reaches a visual score of 4, 3, 2
and 1 at imatinib concentrations of 0, 5, 10 and 15 mM, respectively.
Phase contrast microscopy (1006). B. HTAMC outgrowth from normal
(solid bars) and GCA involved (white bars) temporal artery sections
exposed to various imatinib concentrations, measured at day 15. C.
Effect of imatinib mesylate on myointimal cell outgrowth from an aortic
fragment of a GCA-related aortic aneurysm.
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